Asthma Drugs Market Status, Future Forecast, Growth Opportunity, Key Market, Key Players 2024-2033

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033.

The Business Research Company offers in-depth market insights through Asthma Drugs Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The asthma drugs market size has grown strongly in recent years. It will grow from $23.05 billion in 2023 to $24.25 billion in 2024 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to environmental factors, increased respiratory disorders, lifestyle changes, healthcare infrastructure development.

The asthma drugs market size is expected to see strong growth in the next few years. It will grow to $30 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to rising air pollution levels, growing aging population, increasing healthcare awareness, personalized medicine trends, biopharmaceutical innovations. Major trends in the forecast period include small molecule therapies, home-based asthma care, biomarker-guided therapies, therapeutic advances in severe asthma, collaborations for asthma research.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=11924&type=smp

Market Segmentation:
The asthma drugs market covered in this report is segmented -
1) By Type Of Asthma: Allergic, Non-Allergic
2) By Asthma Trigger Type: Adult-Onset Asthma, Child-Onset Asthma, Cough-Induced Asthma, Exercise-Induced Asthma, Occupational Asthma, Nocturnal Asthma, Steroid-Resistant Asthma
3) By Therapy: Preventive, Curative
4) By Drug Class: Bronchodilators, Monoclonal Antibodies, Anti-Inflammatory Drugs, Combination Drugs
5) By End-User: Asthma Patients, COPD Patients

Major Driver - Soaring Prevalence Of Asthmatic Disorders Propels Growth In The Asthma Drug Market
The high prevalence of asthmatic disorders is expected to propel the growth of the asthma drug market going forward. Asthma refers to a long-term disease that causes inflammation and swelling of the airways, resulting in the narrowing of the airways that carry air from the nose and mouth to the lungs. Owing to the increase in asthma cases, there has been a surge in the identification of new asthma drugs for treating asthmatic disorders. For instance, in May 2023, according to the Centers for Disease Control and Prevention, a US-based national public health agency, in the US asthma prevalence increased to 24,96 million in 2021 and there were 3,517 deaths. Therefore, the increasing number of asthmatic disorders leads to an increase in the development of novel drugs, which will further drive the asthma drug market.

Competitive Landscape:
Major companies operating in the asthma drugs market report are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca PLC., GlaxoSmithKline PLC., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Novartis International AG, Mylan N.V., Koninklijke Philips N.V, Cipla Limited, Chiesi Farmaceutici S.p.A., Sun Pharmaceutical Industries Limited, Hikma Pharmaceuticals, Mundipharma International Limited, Lupin Limited, Glenmark Pharmaceuticals Limited, Hetero Drugs Limited, Alembic Pharmaceuticals Limited, Sunovion Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc., Beximco Pharmaceuticals Ltd, Innoviva Inc., Vectura Group, Circassia Group PLC, Pari Medical Holding GmbH, Pulmatrix Inc., Atopix Therapeutics Limited.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report

Top Trend - Amgen And Astrazeneca Gain FDA Approval For Tezpire, Revolutionizing Asthma Drug Market
Product innovations are a key trend gaining popularity in the asthma drug market. Major companies operating in the asthma drug market are focused on developing new solutions to sustain their position in the market. For instance, in December 2021, Amgen, a US-based biopharmaceutical company, and AstraZeneca, a UK-based biopharmaceutical company, received FDA approval for their injectable drug Tezpire to alleviate the symptoms of asthma. The drug Tezpire helps to sto2p the inflammation that causes asthma attacks and has the potential to treat a wide range of people with severe asthma, including patients who have lacked effective treatment options in the past. The drug is the first and only biologic to reduce asthma-related exacerbations in Phase 2 and 3 clinical trials. significantly and consistently. The approval of Tezpire will enable greater benefits for this medicine for patients owing to the rising number of asthma cases.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Asthma Drugs Market Characteristics
3. Asthma Drugs Market Trends And Strategies
4. Asthma Drugs Market - Macro Economic Scenario
5. Asthma Drugs Market Size And Growth
…..
27. Asthma Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.